|
|
|
|
Vol. 55, Issue 5, 847-854, May 1999
Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan (N.A., T.S., A.C., Y.K., N.N., H.E.); and Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand (N.A., S.S.)
| |
Summary |
|---|
|
|
|---|
Organic anion transporter 1 (OAT1) is the para-aminohippurate (PAH) transporter in the basolateral membrane of the proximal tubule. The present study investigated whether or not nonsteroidal anti-inflammatory drugs (NSAIDs) are transported by OAT1. All of the NSAIDs tested inhibited [14C]PAH uptake via OAT1 expressed in Xenopus laevis oocytes. Ibuprofen, indomethacin, salicylurate, and naproxen showed the strongest potency to inhibit [14C]PAH uptake (Ki ~ 2-10 µM); acetylsalicylate, salicylate, and phenacetin exhibited moderate potency (Ki ~ 300-400 µM), and acetaminophen (paracetamol) exhibited the weakest inhibitory potency (Ki ~ 2 mM). Radiolabeled acetylsalicylate, salicylate, and indomethacin were taken up by OAT1 and the uptake rate of these three NSAIDs was enhanced by the outwardly directed dicarboxylate gradient. The efflux of the preloaded [14C]PAH from the oocytes via OAT1 was trans-stimulated by PAH and glutarate added to the media. The addition of salicylate, acetylsalicylate, or salicylurate into the media also trans-stimulated the efflux of PAH, whereas indomethacin did not. The present study indicates that OAT1 is responsible for the renal uptake and secretion of NSAIDs.
| |
Introduction |
|---|
|
|
|---|
The
kidneys, along with the liver, are the main organs for drug excretion
and metabolism. Three processes are involved in the renal
handling of drugs: glomerular filtration, tubular reabsorption, and
tubular secretion. The tubular secretion of xenobiotics, especially organic anions, has been studied extensively (Sperber, 1959
; Weiner and
Mudge, 1964
; Ullrich and Rumrich, 1988
; Pritchard and Miller, 1991
), and para-aminohippurate (PAH) has been used as
a prototypical substrate for the renal organic anion transport
pathway(s). Previous studies on renal organic anion transport by
micropuncture experiments in vivo and uptake experiments with renal
slices, tubule suspensions, isolated tubules, and culture cells have
suggested that PAH transporter is responsible for the secretion of a
variety of anionic drugs.
In 1997, cDNA encoding a PAH transporter was isolated from rat kidneys
and was designated organic anion transporter 1 (OAT1; Sekine et al.,
1997
). Independently, rat renal organic anion transporter 1 (ROAT1) was isolated, also as a PAH transporter (Sweet et al., 1997
); the amino acid sequence of ROAT1 is identical with that of OAT1.
As had been predicted, OAT1 is a multispecific organic anion
transporter at the basolateral membrane of the middle portion of the
proximal tubule S2 (Sekine et al., 1997
; Tojo et al., 1999
).
Previous studies indicated active accumulation of nonsteroidal
anti-inflammatory drugs (NSAIDs) in the renal proximal tubular cells.
Accumulation of indomethacin and salicylate has been demonstrated in
rat proximal tubular cells (De Zeeuw et al., 1988
; Cox et al., 1992
). In particular, renal handling of salicylate was studied extensively by micropuncture experiments in vivo (Ferrier et al., 1983
), isolated proximal tubules (Schild and Roch-Ramel, 1988
; Cox et
al., 1992
), renal cortical slices (Despopoulos, 1960
, Putney and
Borzelleca, 1973
), and a kidney epithelial cell line (Chatton and
Roch-Ramel, 1992
). In addition, there are also the reports on the
interaction of NSAIDs with other organic anions, such as prostaglandins
(Bito et al., 1976
) and penicillin (Nierenberg, 1986
). The results of
these studies suggest that NSAIDs may be transported via the renal
organic anion transporter.
We already reported that indomethacin potently inhibited
[14C]PAH uptake via OAT1 (Sekine et al., 1997
).
There are many types of NSAIDs with different chemical properties. In
the present study, we aimed to determine whether the various NSAIDs
interact with and are transported by OAT1. Furthermore, we investigated
the transport properties of OAT1 as an exchanger.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. [14C]Salicylate (2.05 GBq/mmol), [14C]PAH (2.0 GBq/mmol), and [14C]indomethacin (0.825 GBq/mmol) were purchased from Du Pont/New England Nuclear (Boston, MA). [14C]Acetylsalicylate (2.0 GBq/mmol) and [14C]glutarate (2.035 GBq/mmol) were purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO). The other NSAIDs were from Sigma Chemical Co. (St. Louis, MO).
cRNA Synthesis and Oocyte Injection.
Capped cRNAs for OAT1
and rat sodium-dependent dicarboxylate transporter (rNaDC-1; Sekine et
al., 1998
) were synthesized in vitro by T7 RNA polymerase, as described
elsewhere (Sekine et al., 1997
). Defolliculated oocytes were injected
with 10 ng of OAT1 cRNA. For coexpression experiments, both OAT1 cRNA
(7.5 ng) and rNaDC-1 cRNA (2.5 ng) were injected into the oocytes.
After injection, the oocytes were incubated for 2 to 3 days in modified Barth's solution containing gentamicin (88 mM NaCl, 1 mM KCl, 0.33 mM
Ca(NO3)2·4H2O,
0.4 mM CaCl2·2H2O, 0.8 mM
MgSO4·7H2O, 2.4 mM
NaHCO3, 10 mM HEPES, and 150 mg/ml gentamicin; pH
7.4) at 18°C.
Transport Assays. Two to 3 days after cRNA injection, oocytes were preincubated in ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES; pH 7.4) containing 1 mM glutarate for 2 h to generate an outwardly directed glutarate gradient. This preincubation with glutarate was performed routinely for all of the following experiments. After washing with ND96, 450 µl of ND96 solution with radiolabeled substrates was added, and the oocytes were incubated for 1 h at 25°C unless otherwise indicated. In the experiment shown in Fig. 4B, control oocytes and oocytes expressing OAT1 were injected with 100 nl of water or 100 nl of 10 mM glutarate 30 min before the uptake experiment with [14C]salicylate. Transport assay was stopped by adding ice-cold ND96 solution to the well and the oocytes were washed five times with the same solution. Radioactivity was counted after solubilizing oocytes with 250 µl of 10% SDS.
Inhibition Study. For inhibition experiments, oocytes expressing only OAT1 were incubated for 1 h in ND96 solution containing 2 µM [14C]PAH in the absence or presence of inhibitors (1 or 5 mM). Acetylsalicylate, salicylate and salicylurate (a metabolite of salicylate), acetaminophen (paracetamol), benzydamine, aminopyrine, and antipyrine were directly dissolved in ND96 solution. Substrates that were hard to dissolve in ND96 solution (meclofenamate, ibuprofen, phenylbutazone, oxyphenbutazone, flurbiprofen, diclofenac, ketoprofen, indomethacin, phenaceten, diflunisal, naproxen, and tolmetin) were first dissolved in ethanol and diluted to 1 mM with ND96 solution. Piroxicam was first dissolved in dimethylsulfoxide and diluted to 1 mM with ND96 solution. The final concentrations of ethanol and dimethylsulfoxide were adjusted to 0.7% and 1%, respectively, for all of these compounds.
Kinetic Analysis.
After preincubation with glutarate,
oocytes expressing only OAT1 were incubated for 1 h in ND96
solution containing different concentrations of PAH in the absence or
presence of inhibitors, and double reciprocal plot analyses were
performed. Ki values were calculated based
on the following equation, when the inhibition was revealed to be
competitive: Ki = concentration of
inhibitor/[(Km PAH with
inhibitor/Km PAH without
inhibitor)
1].
Efflux Experiment. Oocytes injected with both OAT1 and rNaDC-1 cRNA or with only OAT1 cRNA were incubated in 50 µM [14C]PAH or 50 µM [14C]glutarate for 2 h. When [14C]PAH was used as a tracer, oocytes were preincubated with 1 mM glutarate for 2 h before the experiments. The oocytes were washed 5 times in ice-cold ND96 solution and transferred to wells containing 300 µl of ND96 solution with or without 1 mM test substrates. After 90 min of incubation, the radioactivities of the incubation medium and the corresponding oocyte were counted.
Statistical Analyses. The values represent the mean ± S.E.M. The statistical differences were analyzed by unpaired Student's t test.
| |
Results |
|---|
|
|
|---|
Figure 1
summarizes the cis-inhibitory effect of
various NSAIDs on PAH uptake via OAT1. Two µM
[14C]PAH uptake via OAT1 was inhibited by all
NSAIDs (1 mM) that tested significantly (P < .05),
except aminopyrine. A high concentration of aminopyrine (5 mM)
also inhibited the OAT1-mediated uptake of PAH (83.6 ± 3.4%
inhibition). The degree of inhibition was relatively low among
hydrophilic NSAIDs. However, all compounds with higher log P
values strongly inhibited [14C]PAH uptake via
OAT1 (>95%), except phenacetin (60% inhibition). To characterize the
interaction of NSAIDs with OAT1, inhibitory kinetics of
acetylsalicylate, salicylate, salicylurate, paracetamol, naproxen,
oxyphenbutazone, piroxicam, ibuprofen, indomethacin, and phenacetin
were analyzed. The uptake of different concentrations of PAH via OAT1
was determined in the absence and presence of inhibitors
(concentrations of inhibitors are depicted in Table 1). As shown in Fig.
2, Lineweaver-Burk plot analysis of
salicylurate and ibuprofen demonstrated that these two compounds
inhibited OAT1-mediated PAH uptake in a competitive manner. The
calculated Ki values for salicylurate and
ibuprofen were 11 µM and 3.5 µM, respectively (Table 1). The
inhibitions of the other drugs were also revealed to be competitive
(data not shown). The Ki values for each
compound are shown in Table 1. On the basis of the calculated Ki values, the drugs were placed in the
following order in the affinity to OAT1: naproxen > ibuprofen > indomethacin = salicylurate > oxyphenbutazone > piroxicam
salicylate = acetylsalicylate = phenacetin
paracetamol.
|
|
|
Figure 3 shows the uptake of 30 µM
[14C]salicylate, 30 µM
[14C]acetylsalicylate, and 5 µM
[14C]indomethacin in control oocytes, oocytes
expressing rNaDC-1 or OAT1, and oocytes expressing both rNaDC-1 and
OAT1(coexpression). Figure 4A
schematically represents the coexpression system in Xenopus
oocytes, which generates the steep, outwardly directed gradient of
dicarboxylate. Figure 4B shows the membrane localization of OAT1 and
rNaDC-1 in renal proximal tubule cells (Sekine et al., 1998
; Tojo et
al., 1999
). The uptake rates of these three NSAIDs by oocytes
expressing rNaDC-1 are all the same as those by control oocytes. By
contrast, oocytes expressing OAT1 showed significantly higher uptake of
salicylate, acetylsalicylate, and indomethacin. Furthermore, oocytes
expressing both OAT1 and rNaDC-1 took up these compounds more than
those expressing only OAT1.
|
|
When we did not preincubate the oocytes coexpressing OAT1 and rNaDC-1
with glutarate, the cell-associated count of
[14C]salicylate was lower than that of the
coexpressing oocytes with glutarate preload (Fig.
5A). To directly exclude the effect of the coexpression, we performed microinjection of glutarate into oocytes
that express only OAT1. The injection of 100 nl of 10 mM glutarate
before the uptake experiment increased the cell-associated count of
[14C]salicylate (Fig. 5B).
|
Next, we investigated the transport properties of OAT1 as an exchanger
(Fig. 6). Oocytes that coexpress OAT1 and
rNaDC-1 were preloaded with 50 µM
[14C]glutarate for 2 h, and after being
washed, they were transferred to ND96 solution with or without 1 mM
nonradioactive PAH. The left half of Fig. 6A shows that the efflux of
intracellularly accumulated [14C]glutarate was
enhanced by the addition of 1 mM PAH into the medium (open columns,
control versus PAH). Because the efflux of
[14C]glutarate from oocytes expressing only
rNaDC-1 was not influenced by 1 mM PAH (data not shown), the efflux of
[14C]glutarate is considered to be mediated by
OAT1. We also performed efflux experiments with oocytes expressing only
OAT1 (Fig. 6A, right). The efflux of
[14C]glutarate was also stimulated by 1 mM PAH
(open columns, control versus PAH), although the accumulated glutarate
was much smaller (closed columns, coexpression versus OAT1).
|
We also used [14C]PAH as a tracer for the efflux experiment (Fig. 6B). The accumulated [14C]PAH was higher in oocytes coexpressing rNaDC-1 and OAT1 than in those expressing only OAT1 (closed columns, coexpression versus OAT1). The efflux of [14C]PAH via OAT1 was stimulated by the addition of 1 mM PAH, both in oocytes coexpressing rNaDC-1 and OAT1 and in those expressing only OAT1 (Fig. 6B). The efflux of [14C]PAH stimulated by extracellular PAH increased linearly up to 90 min of incubation (Fig. 6B, inset).
We investigated whether or not the NSAIDs trans-stimulated
OAT1-mediated organic anion transport (Fig.
7). Because oocytes coexpressing rNaDC-1
and OAT1 took up a larger amount of PAH, and the efflux rate of PAH is
higher than those expressing only OAT1, we used the coexpression system
for this purpose. Three NSAIDs (acetylsalicylate, salicylate, and
indomethacin) and one metabolite of salicylate (salicylurate) were
examined. As shown in Fig. 7A, acetylsalicylate, salicylate, and
salicylurate significantly promoted [14C]PAH
efflux. Salicylurate was almost as effective as PAH in the stimulation
of [14C]PAH efflux via OAT1. In contrast,
indomethacin did not promote [14C]PAH efflux;
in fact, it significantly depressed the efflux.
|
As for indomethacin, we examined the time course of its effect on PAH efflux. As shown in Fig. 7B, indomethacin revealed the inhibitory effect on the PAH efflux at 90 min of incubation. However, at 15 and 30 min of incubation, neither a trans-stimulation nor a trans-inhibition effect was observed.
| |
Discussion |
|---|
|
|
|---|
The present study demonstrated that PAH transport via OAT1 was
inhibited by NSAIDs possessing different chemical structures. The
results of this study and previous reports (Sekine et al., 1997
)
indicate that OAT1 is a multispecific organic anion transporter. From
kinetic analyses, at least 10 tested drugs showed a competitive inhibitory effect on the PAH uptake via OAT1, suggesting that these
drugs all bound to the binding site of OAT1. Presently, we have no
definite explanations for this multispecific nature of OAT1. Moller and
Sheikh (1983)
suggested that the binding of organic anions with the
renal organic anion transporter depends mainly on hydrophobic, hydrogen
bonding and electrostatic interactions between the substrate and the
carrier. Later, Ullrich and Rumrich (1988)
proposed that PAH
transporter interacts with the substrates that contain hydrophobic
cores with negative charges or negative partial charges. Our results
revealed that all hydrophobic NSAIDs potently inhibited PAH uptake
(except phenacetin), whereas hydrophilic NSAIDs inhibited PAH uptake to
lesser degrees (except salicyluric acid and PAH). Phenacetin, which
possesses the least affinity among the hydrophobic NSAIDs tested,
contains smaller hydrophobic side chains (Table 1). The different
affinity of NSAIDs to OAT1 may signify the importance of hydrophobic
interaction between substrates and OAT1. Large hydrophobic side chains
in the molecules could well stabilize the molecules with the binding
site of OAT1.
Among hydrophobic NSAIDs, phenacetin, piroxicam, oxyphenbutazone, and phenylbutazone possess no carboxylic groups. Phenacetin, piroxicam, and oxyphenbutazone have higher Ki values than ibuprofen and indomethacin, which possess carboxylic groups. This indicates that the negative charge of the substrates increases their affinity to OAT1. The importance of a negative charge is also demonstrated when the affinity among hydrophilic NSAIDs is considered. Small hydrophilic compounds that lack carboxylic groups (paracetamol, aminopyrine, antipyrine) show lower degrees of inhibition to PAH uptake.
Salicylate can be actively accumulated and secreted by proximal renal
tubules (Putney and Borzelleca, 1973
; Weiner, 1973
; Roch-Ramel et al.,
1978
; Ferrier et al., 1983
; Schild and Roch-Ramel, 1988
). The secretory
mechanism of salicylate was suggested to be the same as that for PAH
(Ferrier et al., 1983
). Acetylsalicylate was shown to be accumulated in
renal tissues, although its mechanism is not clearly understood
(Gaspari et al., 1989
). Active accumulation of indomethacin in renal
slices (Cox et al., 1992
) and isolated perfused proximal straight
tubules (De Zeeuw et al., 1988
) was also reported. Salicylate and
indomethacin inhibited PAH uptake by rabbit renal slices with a
Ki of 310 µM and 60 µM, respectively (Nierenberg, 1986
). In rat cortical renal slices (Melendez and Reyes,
1982
), the Ki of indomethacin for PAH
uptake was 11 µM. Some of these Ki values
are slightly lower than those reported from micropuncture experiments
(Ullrich et al., 1990
); however, the inhibition potencies tend to be
similar. It should be noted that these Ki
values of NSAIDs are comparable to those obtained in the present study
for OAT1.
In the results shown in Fig. 3, we demonstrated the significant uptake of salicylate, acetylsalicylate, and indomethacin by OAT1. The uptake of these three NSAIDs via OAT1 was enhanced by the steep, outwardly directed glutarate gradient generated by rNaDC-1. This trans-stimulatory effect of glutarate on the uptake of salicylate, acetylsalicylate, and indomethacin via OAT1 indicates that at least these three NSAIDs not only bind to, but are really translocated by OAT1, because the trans-stimulation occurs only along with the translocation process. The results obtained in the experiments shown in Fig. 5 reinforced the conclusion that salicylate is a transportable substrate of OAT1. These results, together with the fact that the affinity of NSAIDs for OAT1 is similar to those for the renal organic anion transporter, strongly suggest that OAT1 is the major organic anion transporter in the kidney.
The transport rates of salicylate, acetylsalicylate, and indomethacin via OAT1 are low compared with that of PAH. In particular, the transport of indomethacin, despite its high affinity to OAT1 (10 µM), is very small. This result is consistent with the in vivo kinetics: a low rate of administered indomethacin (15%) is excreted into the urine in its original form. The present study indicates that at the molecular level, salicylate, acetylsalicylate, and indomethacin are transportable substrates of OAT1. Nonetheless, NSAIDs, especially the hydrophobic ones, may act rather as inhibitors for the organic anion transporter in the kidney. Although OAT1 accepts a number of compounds, their chemical structures are considerably different. The transport of substrates by carrier proteins consists of three processes: substrate binding, translocation, and dissociation. Among the chemically heterogeneous substances, not only the binding, but also the translocation and dissociation processes, are presumed to be different. Thus, it is no wonder that differences exist in the efficiency of substrates transport by a multispecific transporter like OAT1.
In previous studies, it was proposed that the basolateral uptake of
organic anions at the middle portion of the proximal tubule (S2
segment) is mediated by a dicarboxylate/organic anion exchanger (Shimada et al., 1987
; Pritchard and Miller, 1991
) and we also suggested that OAT1 is an organic anion/dicarboxylate exchanger (Sekine
et al., 1997
). In the present study, we analyzed the efflux of
substrates via OAT1 to confirm this exchange model. When oocytes expressing OAT1 were preloaded with [14C]PAH or
[14C]glutarate and were transferred to the
incubation medium containing PAH, the efflux of
[14C]PAH or
[14C]glutarate was stimulated. When we
considered this result in conjunction with the previous observation
that preloading the oocytes expressing OAT1 with glutarate stimulated
the uptake of [14C]PAH via OAT1, it is clear
that OAT1 is, indeed, an exchanger. Furthermore, the fact that not only
dicarboxylate (glutarate), but also PAH itself, is effluxed from the
oocytes expressing OAT1, suggests that the intracellular binding site
of OAT1 is also multispecific. OAT1 can act as both a heteroexchanger
(dicarboxylate/PAH exchange) and homoexchanger (PAH/PAH exchange) and
there seems to be no strict rectification in the transmembrane
transport via OAT1. Our results, that the addition of PAH to the
extracellular compartment could stimulate the efflux of preloaded PAH,
are consistent with the in vitro experiment with isolated S2 segments
of proximal tubules (Chatsudthipong and Dantzler, 1992
).
Three of the NSAIDs tested and salicylurate showed different
actions on [14C]PAH efflux. Salicylate,
acetylsalicylate, and salicylurate clearly induced the efflux of PAH.
This result suggests that these three compounds are actually
transported via OAT1 by the exchange mechanism. This was supported by
the result of the uptake experiment with radiolabeled acetylsalicylate
and salicylate (Fig. 3). On the contrary, indomethacin depressed
[14C]PAH efflux during 90 min of incubation.
Short-time incubation with indomethacin did not show significant
depression. There are at least two possibilities for the suppression of
PAH efflux by indomethacin. One possibility is that these compounds
simply diffuse into the cells because of their high hydrophobicity and
compete with [14C]PAH at the intracellular
binding site of OAT1, as suggested by Huang and Lin (1965)
. The fact
that only the long-time incubation revealed depressed efflux may
support this possibility. The other possible mechanism is that
hydrophobic NSAIDs may slow down the translocation process and/or
dissociation of the transporter after binding to OAT1. This possibility
has already been considered in the experiment with probenecid (Dantzler
et al., 1995
) and is also supported by the finding that substitution of
phenolsulfophthalein dyes by a hydrophobic core inhibits their movement
by the organic anion transport system in rabbit (Sheikh, 1976
).
Although further experiments are needed to substantiate these
possibilities, we propose that this efflux system can be used for the
determination of transportable substrates. If the tested compounds can
induce the efflux of intracellularly accumulated anion, they are
considered to be transportable substrates.
OAT1 may also be responsible for drug metabolism and renal toxicity.
With regard to drug metabolism, there is evidence that salicylate can
be converted to salicylurate (Bekersky et al., 1980
; Laznicek and
Laznickova, 1994
) and acetylsalicylate to salicylate in kidneys
(Gaspari et al., 1989
). There has been a report that hydrolases
responsible for converting aspirin to salicylate were found in kidneys
of various species, including humans and rats (Eyring and Ford, 1972
).
Furthermore, proximal tubules, especially the S2 segments, are very
rich in drug-metabolizing enzymes, i.e., cytochrome P-450-dependent
mixed function oxidase (Endou et al., 1982). This coincides with the
high expression of OAT1 in S2 segments (Tojo et al., 1999
). OAT1 may be
responsible for the transport of organic anions into the proximal
tubular cells where the drug-metabolizing enzymes exist. In regard to
drug-induced nephrotoxicity, there are reports showing that
acetylsalicylate could induce renal papillary necrosis (Axelsen, 1976
;
Molland, 1976
) and proximal tubular cell damage (Molland, 1976
).
Salicylate was also reported to cause necrosis of renal papilla
(Fellers et al., 1965
). Uptake of acetylsalicylate via OAT1 may be
responsible for acetylsalicylate accumulation in the cells or it could
be further metabolized to salicylate. Subsequent secretion of these
drugs into the lumen may lead to high concentrations of the drugs in
papillary tips, causing renal papillary necrosis. Moreover, it was
found that cortical tubular necrosis induced by either acetylsalicylate
or oxyphenbutazone was reduced when probenecid, a potent inhibitor of
organic anion transporters, was administered concomitantly (Arnold et
al., 1976
). Thus, OAT1 may be one of the factors responsible for
drug-induced nephrotoxicity.
| |
Acknowledgments |
|---|
We are grateful to Miwako Nishizono for technical assistance.
| |
Footnotes |
|---|
Received August 31, 1998; Accepted February 12, 1999
This work was supported in part by grants from the Japanese Ministry of Education, Science, Sports, and Culture; the Science Research Promotion Fund of the Japan Private School Promotion Foundation; Uehara Memorial Foundation; and the Tokyo Biochemical Research Foundation.
Send reprint requests to: Dr. Hitoshi Endou, Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan. E-mail: endouh{at}kyorin-u.ac.jp
| |
Abbreviations |
|---|
OAT1, organic anion transporter 1; rNaDC-1, rat sodium-dependent dicarboxylate transporter; PAH, para-aminohippurate; NSAID, nonsteroidal anti-inflammatory drug.
| |
References |
|---|
|
|
|---|
-KG countertransport stimulates PAH uptake and net secretion in isolated rabbit renal tubules.
Am J Physiol
263:
F384-F391This article has been cited by other articles:
![]() |
Y. Nozaki, H. Kusuhara, T. Kondo, M. Iwaki, Y. Shiroyanagi, H. Nakayama, S. Horita, H. Nakazawa, T. Okano, and Y. Sugiyama Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1162 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nozaki, H. Kusuhara, T. Kondo, M. Hasegawa, Y. Shiroyanagi, H. Nakazawa, T. Okano, and Y. Sugiyama Characterization of the Uptake of Organic Anion Transporter (OAT) 1 and OAT3 Substrates by Human Kidney Slices J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 362 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. K. El-Sheikh, J. J. M. W. van den Heuvel, J. B. Koenderink, and F. G. M. Russel Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 229 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mannila, E. Kumpulainen, M. Lehtonen, M. Heikkinen, M. Laisalmi, T. Salo, J. Rautio, J. Savolainen, and H. Kokki Plasma and Cerebrospinal Fluid Concentrations of Indomethacin in Children After Intravenous Administration J. Clin. Pharmacol., January 1, 2007; 47(1): 94 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Schnabolk, G. L. Youngblood, and D. H. Sweet Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20) Am J Physiol Renal Physiol, August 1, 2006; 291(2): F314 - F321. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Eraly, V. Vallon, D. A. Vaughn, J. A. Gangoiti, K. Richter, M. Nagle, J. C. Monte, T. Rieg, D. M. Truong, J. M. Long, et al. Decreased Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic Anions in OAT1 Knock-out Mice J. Biol. Chem., February 24, 2006; 281(8): 5072 - 5083. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. O'Donnell and M. R. Rheault Ion-selective microelectrode analysis of salicylate transport by the Malpighian tubules and gut of Drosophila melanogaster J. Exp. Biol., January 1, 2005; 208(1): 93 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nozaki, H. Kusuhara, H. Endou, and Y. Sugiyama Quantitative Evaluation of the Drug-Drug Interactions between Methotrexate and Nonsteroidal Anti-Inflammatory Drugs in the Renal Uptake Process Based on the Contribution of Organic Anion Transporters and Reduced Folate Carrier J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 226 - 234. [Abstract] [Full Text] |
||||
![]() |
N. Shikano, Y. Kanai, K. Kawai, N. Ishikawa, and H. Endou Transport of 99mTc-MAG3 via Rat Renal Organic Anion Transporter 1 J. Nucl. Med., January 1, 2004; 45(1): 80 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Jutabha, Y. Kanai, M. Hosoyamada, A. Chairoungdua, D. K. Kim, Y. Iribe, E. Babu, J. Y. Kim, N. Anzai, V. Chatsudthipong, et al. Identification of a Novel Voltage-driven Organic Anion Transporter Present at Apical Membrane of Renal Proximal Tubule J. Biol. Chem., July 18, 2003; 278(30): 27930 - 27938. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Aslamkhan, Y.-H. Han, X.-P. Yang, R. K. Zalups, and J. B. Pritchard Human Renal Organic Anion Transporter 1-Dependent Uptake and Toxicity of Mercuric-Thiol Conjugates in Madin-Darby Canine Kidney Cells Mol. Pharmacol., March 1, 2003; 63(3): 590 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khamdang, M. Takeda, R. Noshiro, S. Narikawa, A. Enomoto, N. Anzai, P. Piyachaturawat, and H. Endou Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 534 - 539. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, M. Hosoyamada, S. H. Cha, T. Sekine, and H. Endou Characterization of Methotrexate Transport and Its Drug Interactions with Human Organic Anion Transporters J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 666 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Enomoto, M. Takeda, A. Tojo, T. Sekine, S. H. Cha, S. Khamdang, F. Takayama, I. Aoyama, S. Nakamura, H. Endou, et al. Role of Organic Anion Transporters in the Tubular Transport of Indoxyl Sulfate and the Induction of its Nephrotoxicity J. Am. Soc. Nephrol., July 1, 2002; 13(7): 1711 - 1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Enomoto, M. Takeda, M. Shimoda, S. Narikawa, Y. Kobayashi, Y. Kobayashi, T. Yamamoto, T. Sekine, S. H. Cha, T. Niwa, et al. Interaction of Human Organic Anion Transporters 2 and 4 with Organic Anion Transport Inhibitors J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 797 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Uchino, Y. Kanai, D. K. Kim, M. F. Wempe, A. Chairoungdua, E. Morimoto, M. W. Anders, and H. Endou Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition Mol. Pharmacol., April 1, 2002; 61(4): 729 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Hill, T. Cihlar, C. Oo, E. S. Ho, K. Prior, H. Wiltshire, J. Barrett, B. Liu, and P. Ward The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion---Correlation of in Vivo and in Vitro Studies Drug Metab. Dispos., January 1, 2002; 30(1): 13 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Islinger, M. Gekle, and S. H. Wright Interaction of 2,3-Dimercapto-1-propane Sulfonate with the Human Organic Anion Transporter hOAT1 J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 741 - 747. |